Price Chart

Key Stats

Net Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
1.06% -0.28% 16.55M 73529.07
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (Since Inception)
1.52% 51.00% 4.568M Upgrade

Basic Info

Investment Strategy
The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class Miscellaneous
Broad Category Miscellaneous
Category Name Trading--Leveraged Equity
Category Index S&P 500 TR USD
Global Category Name Trading Tools
YCharts Categorization Other
YCharts Benchmark S&P 500 Total Return (^SPXTR)
Prospectus Objective Growth and Income
Fund Owner Firm Name Direxion Funds
Prospectus Benchmark Index
S&P Pharms Select Industry TR USD 300.0%
Broad Asset Class Benchmark Index
^SPXTR 100.0%
Manager Tenure
Paul Brigandi 6.22 yrs
Tony Ng 6.22 yrs

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of February 27, 2024. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Loading chart...
Name
2017
2018
2019
2020
2021
2022
2023
YTD
--
-21.15%
19.26%
0.28%
-37.33%
-43.16%
-12.08%
25.29%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
26.29%
6.70%
16.56%
-13.84%
57.88%
-28.07%
88.23%
-49.63%
11.60%
-10.06%
7.56%
-25.11%
82.02%
-55.64%
153.4%
-67.24%
12.06%
-15.16%
40.49%
-24.93%
46.71%
39.79%
-6.02%
-28.85%
-1.05%
9.13%
--
-44.94%
47.96%
-7.37%
105.2%
-58.70%
54.51%
17.64%
As of February 27, 2024.

Asset Allocation

As of February 26, 2024.
Type % Net % Long % Short
Cash 11.31% Upgrade Upgrade
Stock 88.69% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Basic Info

Investment Strategy
The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class Miscellaneous
Broad Category Miscellaneous
Category Name Trading--Leveraged Equity
Category Index S&P 500 TR USD
Global Category Name Trading Tools
YCharts Categorization Other
YCharts Benchmark S&P 500 Total Return (^SPXTR)
Prospectus Objective Growth and Income
Fund Owner Firm Name Direxion Funds
Prospectus Benchmark Index
S&P Pharms Select Industry TR USD 300.0%
Broad Asset Class Benchmark Index
^SPXTR 100.0%
Manager Tenure
Paul Brigandi 6.22 yrs
Tony Ng 6.22 yrs

Top Portfolio Holders

0 of 0